Pharma Marketletter , 02/21/2005
Evotec and AnorMED sign process validation deal.(pharmaceutical industry)(Brief Article)
COPYRIGHT 2005 Marketletter Publications Ltd.
Germany's Evotec OAI AG, a provider of integrated, high-value-added drug discovery and development solutions, says it has been selected by Canadian drugmaker AnorMED to support the chemical development of its candidate, AMD 3100, which is under clinical evaluation in stem-cell mobilization for stem-cell transplantation in cancer patients. Using its chemical and pharmaceutical development platform EVOdevelop, the German firm will undertake the full validation of the process to AMD 3100, including process R&D, analytical work and Good Manufacturing Practice-compliant documentation for subsequent dossier filing, the group said. Further terms of the arrangement were not disclosed.
InfoTrac OneFile (R)
No comments:
Post a Comment